Biomarin Pharmaceutical (BMRN) Finished Goods (2010 - 2021)
Biomarin Pharmaceutical's (BMRN) quarterly Finished Goods came in at $261.6 million in Q3 2021, down 20.79% YoY from $330.3 million in Q3 2020, and up 3.29% on a QoQ basis from $253.3 million in Q2 2021.
Biomarin Pharmaceutical (BMRN) Finished Goods (2010 - 2021) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 12 years of Finished Goods data on file, last reported at $261.6 million in Q3 2021.
- Quarterly Finished Goods fell 20.79% year-over-year to $261.6 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $261.6 million (down 20.79% YoY) and the FY2020 annual result came in at $313.6 million, up 22.57% from the prior year.
- Finished Goods rose to $261.6 million in Q3 2021, from $253.3 million in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $330.3 million in Q3 2020 to a low of $129.6 million in Q2 2017.
- A 5-year average of $226.5 million and a median of $220.9 million in 2018 frame the typical range for Finished Goods.
- Annual changes were most pronounced in 2018 — Finished Goods soared 70.09% — and 2021, when it retreated 20.79%.
- Tracing BMRN's Finished Goods over 5 years: stood at $191.2 million in 2017, then increased by 17.76% to $225.2 million in 2018, then advanced by 13.62% to $255.9 million in 2019, then gained by 22.57% to $313.6 million in 2020, then fell by 16.56% to $261.6 million in 2021.
- The last three Finished Goods figures came in at $261.6 million (Q3 2021), $253.3 million (Q2 2021), and $279.6 million (Q1 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 261.64 Mn |
| Jun 30, 2021 | 253.30 Mn |
| Mar 31, 2021 | 279.60 Mn |
| Dec 31, 2020 | 313.59 Mn |
| Sep 30, 2020 | 330.31 Mn |
| Jun 30, 2020 | 292.57 Mn |
| Mar 31, 2020 | 251.48 Mn |
| Dec 31, 2019 | 255.86 Mn |
| Sep 30, 2019 | 219.59 Mn |
| Jun 30, 2019 | 208.11 Mn |
| Mar 31, 2019 | 191.47 Mn |
| Dec 31, 2018 | 225.19 Mn |
| Sep 30, 2018 | 210.90 Mn |
| Jun 30, 2018 | 192.45 Mn |
| Mar 31, 2018 | 220.94 Mn |
| Dec 31, 2017 | 191.22 Mn |
| Sep 30, 2017 | 146.20 Mn |
| Jun 30, 2017 | 129.57 Mn |
| Mar 31, 2017 | 129.89 Mn |
| Dec 31, 2016 | 136.09 Mn |